In the latest shareholder lawsuit, a pension fund accused executives at Emergent BioSolutions of insider trading. The company, under investigation by Congress, has halted manufacturing of Covid-19 vaccines at its Baltimore factory at regulators’ request.
source https://www.nytimes.com/2021/07/06/us/emergent-biosolutions-vaccines-investors.html
0 Comments